PMID- 26781332
OWN - NLM
STAT- MEDLINE
DCOM- 20161226
LR  - 20181113
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Print)
IS  - 1791-2997 (Linking)
VI  - 13
IP  - 3
DP  - 2016 Mar
TI  - Treatment with the herbal medicine, naoxintong improves the protective effect of 
      high-density lipoproteins on endothelial function in patients with type 2 
      diabetes.
PG  - 2007-16
LID - 10.3892/mmr.2016.4792 [doi]
AB  - The protective effect of high‑density lipoprotein (HDL) on endothelial function 
      is impaired in patients with type 2 diabetes mellitus (T2DM), which may result in 
      atherosclerotic complications. Naoxintong (NXT) is a compound preparation that 
      includes Radix Astragali, Angelicae sinensis, Radix Paeoniae Rubra and Ligusticum 
      wallichii. It is widely administered in China to prevent atherosclerotic 
      complications. In the present study, NXT was administered to 69 patients with 
      T2DM. HDLs were isolated from patient blood samples prior to and following the 
      intervention. In vitro endothelial functions of HDL, including proliferation, 
      migration, angiogenesis, and anti‑apoptosis were investigated by 
      bromodeoxyuridine, wound healing, Transwell and Matrigel tube formation assays on 
      human umbilical vein endothelial cells (HUVECs). The results from the present 
      study demonstrated that HUVECs treated with HDL isolated from diabetic patients 
      following NXT therapy exhibited increased proliferative effects (10‑27%; P<0.05), 
      and improved migration ability (15‑35%; P<0.05), anti‑apoptotic function (23‑34%; 
      P<0.05) and angiogenesis (30‑54%; P<0.001). Furthermore, the phosphorylation 
      levels of Akt (26‑36%; P<0.01) and extracellular signal‑regulated kinase (16‑80%; 
      P<0.01) were increased following NXT therapy. The present in vitro study 
      demonstrates that the protective effect of HDL on endothelial function is 
      markedly impaired in diabetic patients who tend to develop atherosclerosis, and 
      the impaired function may be partly abrogated by NXT.
FAU - Lv, Pu
AU  - Lv P
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Tong, Xunliang
AU  - Tong X
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Peng, Qing
AU  - Peng Q
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Liu, Yuanyuan
AU  - Liu Y
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Jin, Haiqiang
AU  - Jin H
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Liu, Ran
AU  - Liu R
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Sun, Wei
AU  - Sun W
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
FAU - Pan, Bing
AU  - Pan B
AD  - The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, 
      School of Basic Medical Sciences, and Key Laboratory of Molecular Cardiovascular 
      Sciences, Ministry of Education, Key Laboratory of Cardiovascular Molecular 
      Biology and Regulatory Peptides, Ministry of Health, Peking University Health 
      Science Center, Beijing 100191, P.R. China.
FAU - Zheng, Lemin
AU  - Zheng L
AD  - The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, 
      School of Basic Medical Sciences, and Key Laboratory of Molecular Cardiovascular 
      Sciences, Ministry of Education, Key Laboratory of Cardiovascular Molecular 
      Biology and Regulatory Peptides, Ministry of Health, Peking University Health 
      Science Center, Beijing 100191, P.R. China.
FAU - Huang, Yining
AU  - Huang Y
AD  - Department of Neurology, Peking University First Hospital, Beijing 100034, P.R. 
      China.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160118
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Lipoproteins, HDL)
RN  - 0 (Protective Agents)
RN  - 0 (naoxintong)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Apoptosis/drug effects
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Diabetes Mellitus, Type 2/*drug therapy/pathology/*physiopathology
MH  - Drugs, Chinese Herbal/pharmacology/*therapeutic use
MH  - Endothelial Cells/drug effects/metabolism/*pathology
MH  - Enzyme Activation/drug effects
MH  - Extracellular Signal-Regulated MAP Kinases/metabolism
MH  - Female
MH  - Herbal Medicine
MH  - Human Umbilical Vein Endothelial Cells/drug effects/metabolism
MH  - Humans
MH  - Lipoproteins, HDL/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Neovascularization, Physiologic/drug effects
MH  - Phosphorylation/drug effects
MH  - Phytotherapy
MH  - Protective Agents/*metabolism
MH  - Proto-Oncogene Proteins c-akt/metabolism
PMC - PMC4768949
EDAT- 2016/01/20 06:00
MHDA- 2016/12/27 06:00
PMCR- 2016/01/18
CRDT- 2016/01/20 06:00
PHST- 2015/02/28 00:00 [received]
PHST- 2015/12/23 00:00 [accepted]
PHST- 2016/01/20 06:00 [entrez]
PHST- 2016/01/20 06:00 [pubmed]
PHST- 2016/12/27 06:00 [medline]
PHST- 2016/01/18 00:00 [pmc-release]
AID - mmr-13-03-2007 [pii]
AID - 10.3892/mmr.2016.4792 [doi]
PST - ppublish
SO  - Mol Med Rep. 2016 Mar;13(3):2007-16. doi: 10.3892/mmr.2016.4792. Epub 2016 Jan 
      18.